Laboratorios Farmaceuticos Rovi (41L) Financial Statements
Laboratorios Farmaceuticos Rovi Financial Overview
Laboratorios Farmaceuticos Rovi's market cap is currently $3.16B. The company's EPS TTM is $3.62; its P/E ratio is 17.28; and it has a dividend yield of 1.25%. Laboratorios Farmaceuticos Rovi has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 743.48M | $ 763.75M | $ 829.51M | $ 817.70M | $ 648.68M |
| Gross Profit | $ 451.65M | $ 478.35M | $ 483.34M | $ 519.61M | $ 384.82M |
| Operating Income | $ 173.14M | $ 179.54M | $ 220.25M | $ 255.85M | $ 181.57M |
| EBITDA | $ 203.52M | $ 207.69M | $ 245.81M | $ 281.49M | $ 204.72M |
| Net Income | $ 140.44M | $ 136.88M | $ 170.34M | $ 199.67M | $ 153.08M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 97.98M | $ 27.41M | $ 25.32M | $ 124.94M | $ 99.03M |
| Total Assets | $ 955.69M | $ 832.02M | $ 799.88M | $ 878.70M | $ 732.68M |
| Total Debt | $ 121.72M | $ 114.41M | $ 65.43M | $ 72.14M | $ 73.14M |
| Net Debt | $ 23.75M | $ 87.22M | $ 40.10M | $ -52.81M | $ -25.89M |
| Total Liabilities | $ 276.79M | $ 250.48M | $ 256.39M | $ 357.32M | $ 261.70M |
| Stockholders' Equity | $ 664.41M | $ 572.03M | $ 539.39M | $ 520.01M | $ 470.98M |
| Cash Flow | |||||
| Free Cash Flow | $ 120.16M | $ 76.06M | $ 58.06M | $ 186.21M | $ 108.50M |
| Operating Cash Flow | $ 185.37M | $ 138.28M | $ 113.25M | $ 237.60M | $ 149.44M |
| Investing Cash Flow | $ -67.56M | $ -81.06M | $ -52.03M | $ -57.15M | $ -40.84M |
| Financing Cash Flow | $ -47.02M | $ -55.36M | $ -160.84M | $ -154.54M | $ -62.73M |
Currency in EUR
